News | Annuloplasty Rings | October 30, 2017

Second Micro Interventional Devices Annuloplasty System Successfully Implanted

Company plans to initiate first-in-human percutaneous portion of STTAR Study in Q4 2017

Second Micro Interventional Devices Annuloplasty System Successfully Implanted

October 30, 2017 — Micro Interventional Devices Inc. (MID) recently announced the second successful implantation of its MIA (Minimally Invasive Annuloplasty) technology. The patient was enrolled in the first arm of the STTAR (Study of Transcatheter Tricuspid Annular Repair) clinical trial studying the safety and efficacy of MID's MIA device designed to eliminate or greatly reduce tricuspid regurgitation

This is the second patient enrolled in the surgical arm of the STTAR study utilizing a bicuspidization approach. The procedure took less than 14 minutes. The rapid, reproducible deployment of the MIA implant resulted in a 24 percent reduction in annular area and a reduction in tricuspid valve regurgitation from moderate regurgitation pre-procedure to trace regurgitation post-procedure. As with the other four STTAR cases, there were no intraoperative complications or adverse events observed or reported.   

Enrollment in the surgical arm of the STTAR Trial continues with Prof. Kestutis Rucinskas, M.D., chief of cardiac surgery, and Prof. Audrius Aidietis, M.D., chief of cardiology and angiology, at the Vilnius University Hospital Santariskiu Clinic in Vilnius, Lithuania.

The percutaneous arm of the STTAR study is anticipated to commence in Q4 2017. Preclinical testing of the delivery catheter at major universities has proven that MID's 12 French delivery system is effective under imaging guidance in procedures completed in less than one hour. The delivery system is simple to use, according to MID, and it is anticipated that the low mass implant will preserve physiological function and all future options for intervention, differentiating MID from other players in the tricuspid space.

MIA utilizes proprietary, compliant PolyCor anchors, the world's first low-mass polymeric implant designed to comply with normal physiological valvular function. The MIA implant is engineered to plicate and comply with cardiac tissue once deployed.

For more information: www.microinterventional.com

Related Content

LivaNova Receives FDA Clearance for Memo 4D Semi-Rigid Mitral Annuloplasty Ring
Technology | Annuloplasty Rings | June 15, 2018
LivaNova PLC announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Memo 4D semi-rigid...
HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings | July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
TITAN II Trial, Carillon Mitral Contour System, Cardiac Dimensions, Open Heart journal, functional mitral regurgitation, FMR
News | Annuloplasty Rings | July 20, 2016
New data from the TITAN II trial confirm the safety and efficacy of the Carillon Mitral Contour System in the treatment...
Mitralign Percutaneous Annuloplasty System, MPAS, CE Mark approval
News | Annuloplasty Rings | April 27, 2016
Mitralign Inc. announced its Mitralign Percutaneous Annuloplasty System (MPAS) has received CE mark approval from its...
Carillon mitral contour system, Cardiac Dimensions, functional mitral regurgitation, FMR, University Hospital Liepzig study
News | Annuloplasty Rings | February 24, 2016
A single-center study noted that treatment with Cardiac Dimensions’ Carillon Mitral Contour System resulted in...
Carillon mitral contour system, cost-effective, optimal medical treatment, OMT, TITAN, functional mitral regurgitation, FMR

Carillon mitral contour system image courtesy of Cardiac Dimensions Inc.

News | Annuloplasty Rings | September 10, 2015
The Carillon mitral contour system is projected to be a cost-effective treatment option when compared to a typical...
Overlay Init